Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.
5/5 보강
TL;DR
In this pilot study, 9 of 12 patients treated with ruxolitinib showed significant scalp hair regrowth and improvement of AA, andGene expression profiling revealed treatment-related downregulation of inflammatory markers, including signatures for CTLs and IFN response genes and upregulation of hair-specific markers.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
12 patients with moderate-to-severe AA, using oral ruxolitinib, 20 mg twice per day, for 3-6 months of treatment followed by 3 months follow-up off drug.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Clinicaltrials.gov NCT01950780. Locks of Love Foundation, the Alopecia Areata Initiative, NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and the Irving Institute for Clinical and Translational Research/Columbia University Medical Center Clinical and Translational Science Award (CUMC CTSA).
📑 코퍼스 인용 관계
· 인용됨 86 · 인용함 24
→ 이 논문이 인용한 논문 (6) ▾
- Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and al… Journal of the American Academy of Dermatology · 2016
- Molecular signatures define alopecia areata subtypes and transcriptional biomarkers. EBioMedicine · 2016
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia are… JCI insight · 2016
- Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocy… American journal of hematology · 2015
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine · 2015
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nature medicine · 2014
📑 인용한 논문 (6) ▾
- Performance exploration of multi-gene panels of alopecia areata susceptibility and drug-bi… Frontiers in physiology · 2025
- Meta-Analysis of Gene Expression Reveals the Core Transcriptomic Profile of Lesional Scalp… Dermatology and therapy · 2025
- Unveiling the Effect of Age and IgE Level on Alopecia Areata: Insights from Comparative RN… Clinical, cosmetic and investigational dermatology · 2025
- Efficacy of Oral Tofacitinib in Alopecia Areata, Alopecia Totalis, and Alopecia Universali… Cureus · 2025
- Comprehensive Review on Hair Loss and Restorative Techniques: Advances in Diagnostic, Arti… Cureus · 2025
- Alopecia Areata: Pathogenesis, Diagnosis, and Therapies. MedComm · 2025
연도별 인용 (2016–2026) · 합계 282
OpenAlex 토픽 ·
Hair Growth and Disorders
melanin and skin pigmentation
Autoimmune Bullous Skin Diseases
🇰🇷 한글 요약 🌐 Abstract
【연구 목적】
중등도-중증 원형 탈모증(alopecia areata, AA) 환자를 대상으로 경구 JAK1/2 억제제 룩솔리티닙(ruxolitinib)의 모발 재성장 효과와 안전성을 평가하기 위한 공개 라벨 임상시험.
【방법】
중등도-중증 AA 환자 12명에게 경구 룩솔리티닙 20mg을 1일 2회, 3-6개월간 투여 후 3개월 추적 관찰한 공개 라벨 연구(NCT01950780). 1차 평가지표는 기저치 대비 50% 이상 모발 재성장을 보인 환자 비율이며, 두피 조직의 유전자 발현 프로파일링을 병행함.
【주요 결과】
12명 중 9명(75%)이 치료에 반응하여 평균 92%의 모발 재성장을 보였으며, 중대한 이상반응은 보고되지 않음. 유전자 발현 분석에서 세포독성 T림프구(CTL) 및 IFN-γ 반응 유전자 등 염증 표지자의 하향 조절과 모발 특이 표지자의 상향 조절이 확인됨.
【임상적 시사점 (성형외과 의사 관점)】
모발이식 적응증이 되지 않는 광범위 원형 탈모증 환자에게 약물치료 대안으로 JAK 억제제를 고려할 수 있으며, 모발이식 전 활동성 AA 병변의 안정화 목적으로도 활용 가능성 있음. 다만 본 연구는 12명 소규모 파일럿이므로 환자 상담 시 대규모 RCT 근거 부족 및 장기 안전성 미확립을 반드시 설명해야 함.
Alopecia areata (AA) is a common autoimmune disease with a lifetime risk of 1.7%; there are no FDA-approved treatments for AA. We previously identified a dominant IFN-γ transcriptional signature in cytotoxic T lymphocytes (CTLs) in human and mouse AA skin and showed that treatment with JAK inhibitors induced durable hair regrowth in mice by targeting this pathway. Here, we investigated the use of the oral JAK1/2 inhibitor ruxolitinib in the treatment of patients with moderate-to-severe AA. We initiated an open-label clinical trial of 12 patients with moderate-to-severe AA, using oral ruxolitinib, 20 mg twice per day, for 3-6 months of treatment followed by 3 months follow-up off drug. The primary endpoint was the proportion of subjects with 50% or greater hair regrowth from baseline to end of treatment. Nine of twelve patients (75%) demonstrated a remarkable response to treatment, with average hair regrowth of 92% at the end of treatment. Safety parameters remained largely within normal limits, and no serious adverse effects were reported. Gene expression profiling revealed treatment-related downregulation of inflammatory markers, including signatures for CTLs and IFN response genes and upregulation of hair-specific markers. In this pilot study, 9 of 12 patients (75%) treated with ruxolitinib showed significant scalp hair regrowth and improvement of AA. Larger randomized controlled trials are needed to further assess the safety and efficacy of ruxolitinib in the treatment of AA. Clinicaltrials.gov NCT01950780. Locks of Love Foundation, the Alopecia Areata Initiative, NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and the Irving Institute for Clinical and Translational Research/Columbia University Medical Center Clinical and Translational Science Award (CUMC CTSA).
【연구 목적】 중등도-중증 원형 탈모증(alopecia areata, AA) 환자를 대상으로 경구 JAK1/2 억제제 룩솔리티닙(ruxolitinib)의 모발 재성장 효과와 안전성을 평가하기 위한 공개 라벨 임상시험.
APA 7
Mackay-Wiggan, J., Jabbari, A., Nguyen, N., Cerise, J. E., Clark, C., Ulerio, G., Furniss, M., Vaughan, R., Christiano, A. M., & Clynes, R. (2016). Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.. JCI insight, 1(15), e89790. https://doi.org/10.1172/jci.insight.89790
Vancouver
Mackay-Wiggan J, Jabbari A, Nguyen N, Cerise JE, Clark C, Ulerio G, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI insight. 2016;1(15):e89790. doi:10.1172/jci.insight.89790
AMA 11
Mackay-Wiggan J, Jabbari A, Nguyen N, Cerise JE, Clark C, Ulerio G, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI insight. 2016;1(15):e89790. doi:10.1172/jci.insight.89790
Chicago
Mackay-Wiggan, J., Jabbari, A., Nguyen, N., Cerise, J. E., Clark, C., Ulerio, G., Furniss, M., Vaughan, R., Christiano, A. M., and Clynes, R.. 2016. "Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata." JCI insight 1 (15): e89790. https://doi.org/10.1172/jci.insight.89790
MLA 9
Mackay-Wiggan, J., et al. "Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata." JCI insight, vol. 1, no. 15, 2016, pp. e89790. doi:10.1172/jci.insight.89790.
PMID
27699253 ↗
추출된 의학 개체 (NER)
전체 NER 표 보기
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 질환 | alopecia areata
|
원형 탈모증 | dict | 3 | |
| 질환 | alopecia areata
|
원형 탈모증 | dict | 3 | |
| 해부 | scalp
|
두피 | dict | 1 | |
| 해부 | scalp
|
두피 | dict | 1 |
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 13/16 (81%)
· 참조 6편 · 후속 7편
이 논문이 참조한 문헌 24
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.
- Genome-wide association study in alopecia areata implicates both innate and adaptive immunity.
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
- Alopecia areata update: part II. Treatment.
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.
- Molecular signatures define alopecia areata subtypes and transcriptional biomarkers.
- Interventions for alopecia areata.
- Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia.
- Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia are…
- Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study.
이 논문을 인용한 후속 연구 20
- Alopecia areata.
- Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management.
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
- Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options.
- An overview of JAK/STAT pathways and JAK inhibition in alopecia areata.
- The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meanin…
- Functional complexity of hair follicle stem cell niche and therapeutic targeting of niche dysfunctio…
- Pathomechanisms of immune-mediated alopecia.
- JAK inhibitors in dermatology: The promise of a new drug class.
- Treatment of Alopecia Areata With Tofacitinib.
- The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis…
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm.
- JAK Inhibitors for Treatment of Alopecia Areata.
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata.
- Baricitinib for the Treatment of Alopecia Areata.
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata.
- The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Res…
- Tofacitinib for the treatment of lichen planopilaris: A case series.
- Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs.
- The current state of knowledge of the immune ecosystem in alopecia areata.
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
📖 비슷한 OA 논문 — 같은 카테고리, 무료 전문 가능
-
Alopecia areata.
TL;DRAlopecia areata is difficult to manage medically, but recent advances in understanding the molecular mechanisms have revealed new treatments and the possibility of remission in the…
-
Epidemiology and burden of alopecia areata: a systematic review.
TL;DRAA is the most prevalent autoimmune disorder and the second most prevalent hair loss disorder after androgenetic alopecia, and the lifetime risk in the global population is approxi…
-
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
TL;DRIn two phase 3 trials involving patients with severe alopecia areata, oral baricitinib was superior to placebo with respect to hair regrowth at 36 weeks.
-
Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.
TL;DRAlthough a variety of medical, surgical, light‐based and nutraceutical treatment options are available to slow or reverse the progression of AGA, it can be challenging to select ap…
-
Hair follicle immune privilege and its collapse in alopecia areata.
TL;DRA key goal for effective AA management is the re‐establishment of a functional HF IP, which will also provide superior protection from disease relapse, and may confer increased sus…